Experienced in Campomelia Cumming Type

Dr. Fernando S. Ovalle

Endocrinology
University Of Alabama Health Services Foundation, PC
2000 6th Ave S, 
Birmingham, AL 
Accepting New Patients
Offers Telehealth
Experienced in Campomelia Cumming Type
University Of Alabama Health Services Foundation, PC
2000 6th Ave S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical Research

Overview

Fernando Ovalle is an Endocrinologist in Birmingham, Alabama. Dr. Ovalle and is rated as an Experienced provider by MediFind in the treatment of Campomelia Cumming Type. His top areas of expertise are Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Low Blood Sugar, and Islet Cell Transplantation. Dr. Ovalle is currently accepting new patients.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Internal Medicine in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
2000 6th Ave S, Birmingham, AL 35233
Other Locations
UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35249

Additional Areas of Focus

Dr. Ovalle has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Completed
Publish Date: February 01, 2023
Intervention Type: Biological, Drug
Study Drugs: AG019 - Low Dose, Teplizumab, AG019 - High Dose, AG019 - Low or High Dose
Study Phase: Phase 1/Phase 2
Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia
Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia
Enrollment Status: Terminated
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
Repurposing of Verapamil as a Beta Cell Survival Therapy in Type 1 Diabetes
Repurposing of Verapamil as a Beta Cell Survival Therapy in Type 1 Diabetes
Enrollment Status: Completed
Publish Date: February 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
G-Pen (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety
Enrollment Status: Completed
Publish Date: October 30, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

57 Total Publications

Attitudes toward pig islet xenotransplantation for type 1 diabetes: a scoping review.
Attitudes toward pig islet xenotransplantation for type 1 diabetes: a scoping review.
Journal: Journal of endocrinological investigation
Published: May 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ovalle's expertise for a condition
ConditionClose
    View All 118 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile